View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsFlowr 過去の業績過去 基準チェック /06主要情報-49.66%収益成長率-20.81%EPS成長率Pharmaceuticals 業界の成長7.33%収益成長率44.06%株主資本利益率-740.24%ネット・マージン-762.84%前回の決算情報30 Sep 2022最近の業績更新Reported Earnings • Dec 01Third quarter 2021 earnings: EPS in line with expectations, revenues disappointThird quarter 2021 results: CA$0.02 loss per share (up from CA$0.073 loss in 3Q 2020). Net loss: CA$8.77m (loss narrowed 9.7% from 3Q 2020). Revenue missed analyst estimates by 15%. Over the next year, revenue is forecast to grow 149%, compared to a 6.9% growth forecast for the industry in Germany.Reported Earnings • Sep 01Second quarter 2021 earnings released: CA$0.02 loss per share (vs CA$0.04 loss in 2Q 2020)Second quarter 2021 results: Net loss: CA$7.20m (loss widened 47% from 2Q 2020).Reported Earnings • Nov 26Third quarter 2020 earnings released: CA$0.07 loss per shareThird quarter 2020 results: Net loss: CA$9.72m (loss narrowed 36% from 3Q 2019).すべての更新を表示Recent updatesお知らせ • Feb 18The Flowr Corporation Requests to Delist from the TSX Venture ExchangeThe Flowr Corporation (the “Company”) announced that in connection with the closing of its previously announced sale transaction under the Companies’ Creditors Arrangement Act (Canada) (the “CCAAProceedings”), all of the former officers and directors of the Company have resigned and the Court has expanded the powers of Ernst & Young Inc., which acts as the Court appointed Monitor under the CCAA Proceedings (the “CCAA Monitor”) in order to oversee the remaining activities in the CCAA Proceedings including any distribution to creditors and the winding down of operations. On account of the Company having no operating business and having sold substantially all of its assets, as well as the resignation of its management and board of directors, the CCAA Monitor has requested that the common shares of the Company be delisted from the TSX Venture Exchange.お知らせ • Feb 04Avant Brands K1 Inc. (formerly 1000343100 Ontario Inc.) completed the acquisition of The Flowr Group (Okanagan) Inc. from The Flowr Corporation (TSXV:FLWR.H) for CAD 5.12 million.1000343100 Ontario Inc. entered into a Stalking Horse Purchase Agreement to acquire The Flowr Group (Okanagan) Inc from The Flowr Corporation (TSXV:FLWR.H) for CAD 0.89 million on November 1, 2022. The transaction is subject to approval by the Ontario Superior Court of Justice,receipt of regulatory approval, the Stalking Horse Purchase Agreement being determined to be the successful bid in the SISP and the Court granting both an order approving the Stalking Horse Purchase Agreement and an Approval and Vesting Order. In the event the Purchaser is not the winning bidder under any such auction, the Stalking Horse Purchase Agreement will be terminated, and the Purchaser will be entitled to payment of a break-up fee in the amount of CAD 0.185 million following closing of the winning bid. The Purchase Price will be satisfied through (a) a credit bid of the DIP Loan in a principal amount of CAD 2 million, plus the Closing DIP Amount, if any, and any accrued and unpaid interest, expenses, fees and other amounts thereon, (b) a cash amount equal to the Purchase Price less the Credit Bid in cash, a portion of which may be payable in non-cash consideration in certain circumstances, and (c) the assumption of the Assumed Liabilities. On December 1, 2022 1000343100 Ontario Inc. has entered into a definitive purchase agreement to acquire all of the issued and outstanding shares in the capital of The Flowr Group (Okanagan) Inc. The purchase price payable by 1000343100 Ontario Inc. for the Purchased Shares pursuant to the Purchase Agreement shall be CAD 5,115,000, being equal to (a) CAD4,015,000, and (b) common shares in the capital of Avant with a value of CAD 1.1 million based on the deemed price per Avant Share equal to a 15% discount to the volume weighted average price per Avant Share on the Toronto Stock Exchange for the 10 consecutive trading days preceding the close of trading on the trading day before the Closing Date. The Transaction is expected to close within Q1 of 2023. Jane Dietrich, Jeremy Bornstein, Jeffrey Mikelberg, Kori Williams, Chandimal Nicholas, Jonathan Sherman of Cassels is representing Avant. Avant Brands K1 Inc. (formerly 1000343100 Ontario Inc.) completed the acquisition of The Flowr Group (Okanagan) Inc. from The Flowr Corporation (TSXV:FLWR.H) for CAD 7.7 million on February 3, 2023. The aggregate revised purchase price consists of (a) CAD 3.85 million payable in cash and (b) 7,402,186 common shares in the capital of Avant; plus (i) the amount of the Closing DIP Loan (to the extent not otherwise repaid), to an aggregate of CAD 2.5 million; and (ii) the value of the Assumed Liabilities, subject to certain adjustments (collectively, the “Purchase Price”). On January 31, 2023, the DIP Term Sheet was amended and the principal amount of the DIP Loan was increased by CAD 0.5 million to an aggregate of CAD 2.5 million.Board Change • Sep 24High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. No experienced directors. No highly experienced directors. Director Tom Flow is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Board Change • Jun 02High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. 2 experienced directors. No highly experienced directors. Independent Director Maurice Levesque is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Board Change • Apr 27High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. 2 experienced directors. No highly experienced directors. Independent Director Maurice Levesque is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Reported Earnings • Dec 01Third quarter 2021 earnings: EPS in line with expectations, revenues disappointThird quarter 2021 results: CA$0.02 loss per share (up from CA$0.073 loss in 3Q 2020). Net loss: CA$8.77m (loss narrowed 9.7% from 3Q 2020). Revenue missed analyst estimates by 15%. Over the next year, revenue is forecast to grow 149%, compared to a 6.9% growth forecast for the industry in Germany.Reported Earnings • Sep 01Second quarter 2021 earnings released: CA$0.02 loss per share (vs CA$0.04 loss in 2Q 2020)Second quarter 2021 results: Net loss: CA$7.20m (loss widened 47% from 2Q 2020).Is New 90 Day High Low • Feb 11New 90-day high: €0.37The company is up 31% from its price of €0.28 on 13 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.78 per share.Is New 90 Day High Low • Jan 04New 90-day low: €0.20The company is down 23% from its price of €0.27 on 06 October 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €3.07 per share.Is New 90 Day High Low • Dec 11New 90-day low: €0.23The company is down 18% from its price of €0.27 on 11 September 2020. The German market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €5.06 per share.Analyst Estimate Surprise Post Earnings • Nov 26Revenue misses expectationsRevenue missed analyst estimates by 0.1%. Over the next year, revenue is forecast to grow 600%, compared to a 2.5% growth forecast for the Pharmaceuticals industry in Germany.Reported Earnings • Nov 26Third quarter 2020 earnings released: CA$0.07 loss per shareThird quarter 2020 results: Net loss: CA$9.72m (loss narrowed 36% from 3Q 2019).Is New 90 Day High Low • Oct 01New 90-day low: €0.25The company is down 31% from its price of €0.36 on 03 July 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €5.50 per share.収支内訳Flowr の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史DB:2VX 収益、費用、利益 ( )CAD Millions日付収益収益G+A経費研究開発費30 Sep 2212-9513130 Jun 2213-9915131 Mar 2212-8414131 Dec 2112-8616230 Sep 2110-11815230 Jun 2110-12016131 Mar 2110-12219131 Dec 208-12622130 Sep 206-4726130 Jun 204-5331131 Mar 204-3635131 Dec 195-3133130 Sep 198-1431030 Jun 197-426031 Mar 194-1920031 Dec 183-1515030 Sep 180-1110030 Jun 180-67031 Mar 180-44031 Dec 170-230質の高い収益: 2VXは現在利益が出ていません。利益率の向上: 2VXは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: 2VXは利益が出ておらず、過去 5 年間で損失は年間49.7%の割合で増加しています。成長の加速: 2VXの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: 2VXは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( 16.1% ) と比較することは困難です。株主資本利益率高いROE: 2VXは現在利益が出ていないため、自己資本利益率 ( -740.24% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/01/15 00:53終値2022/10/18 00:00収益2022/09/30年間収益2021/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋The Flowr Corporation これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関David KideckelATB CormarkNoel AtkinsonClarus Securities Inc.Owen BennettJefferies LLC1 その他のアナリストを表示
Reported Earnings • Dec 01Third quarter 2021 earnings: EPS in line with expectations, revenues disappointThird quarter 2021 results: CA$0.02 loss per share (up from CA$0.073 loss in 3Q 2020). Net loss: CA$8.77m (loss narrowed 9.7% from 3Q 2020). Revenue missed analyst estimates by 15%. Over the next year, revenue is forecast to grow 149%, compared to a 6.9% growth forecast for the industry in Germany.
Reported Earnings • Sep 01Second quarter 2021 earnings released: CA$0.02 loss per share (vs CA$0.04 loss in 2Q 2020)Second quarter 2021 results: Net loss: CA$7.20m (loss widened 47% from 2Q 2020).
Reported Earnings • Nov 26Third quarter 2020 earnings released: CA$0.07 loss per shareThird quarter 2020 results: Net loss: CA$9.72m (loss narrowed 36% from 3Q 2019).
お知らせ • Feb 18The Flowr Corporation Requests to Delist from the TSX Venture ExchangeThe Flowr Corporation (the “Company”) announced that in connection with the closing of its previously announced sale transaction under the Companies’ Creditors Arrangement Act (Canada) (the “CCAAProceedings”), all of the former officers and directors of the Company have resigned and the Court has expanded the powers of Ernst & Young Inc., which acts as the Court appointed Monitor under the CCAA Proceedings (the “CCAA Monitor”) in order to oversee the remaining activities in the CCAA Proceedings including any distribution to creditors and the winding down of operations. On account of the Company having no operating business and having sold substantially all of its assets, as well as the resignation of its management and board of directors, the CCAA Monitor has requested that the common shares of the Company be delisted from the TSX Venture Exchange.
お知らせ • Feb 04Avant Brands K1 Inc. (formerly 1000343100 Ontario Inc.) completed the acquisition of The Flowr Group (Okanagan) Inc. from The Flowr Corporation (TSXV:FLWR.H) for CAD 5.12 million.1000343100 Ontario Inc. entered into a Stalking Horse Purchase Agreement to acquire The Flowr Group (Okanagan) Inc from The Flowr Corporation (TSXV:FLWR.H) for CAD 0.89 million on November 1, 2022. The transaction is subject to approval by the Ontario Superior Court of Justice,receipt of regulatory approval, the Stalking Horse Purchase Agreement being determined to be the successful bid in the SISP and the Court granting both an order approving the Stalking Horse Purchase Agreement and an Approval and Vesting Order. In the event the Purchaser is not the winning bidder under any such auction, the Stalking Horse Purchase Agreement will be terminated, and the Purchaser will be entitled to payment of a break-up fee in the amount of CAD 0.185 million following closing of the winning bid. The Purchase Price will be satisfied through (a) a credit bid of the DIP Loan in a principal amount of CAD 2 million, plus the Closing DIP Amount, if any, and any accrued and unpaid interest, expenses, fees and other amounts thereon, (b) a cash amount equal to the Purchase Price less the Credit Bid in cash, a portion of which may be payable in non-cash consideration in certain circumstances, and (c) the assumption of the Assumed Liabilities. On December 1, 2022 1000343100 Ontario Inc. has entered into a definitive purchase agreement to acquire all of the issued and outstanding shares in the capital of The Flowr Group (Okanagan) Inc. The purchase price payable by 1000343100 Ontario Inc. for the Purchased Shares pursuant to the Purchase Agreement shall be CAD 5,115,000, being equal to (a) CAD4,015,000, and (b) common shares in the capital of Avant with a value of CAD 1.1 million based on the deemed price per Avant Share equal to a 15% discount to the volume weighted average price per Avant Share on the Toronto Stock Exchange for the 10 consecutive trading days preceding the close of trading on the trading day before the Closing Date. The Transaction is expected to close within Q1 of 2023. Jane Dietrich, Jeremy Bornstein, Jeffrey Mikelberg, Kori Williams, Chandimal Nicholas, Jonathan Sherman of Cassels is representing Avant. Avant Brands K1 Inc. (formerly 1000343100 Ontario Inc.) completed the acquisition of The Flowr Group (Okanagan) Inc. from The Flowr Corporation (TSXV:FLWR.H) for CAD 7.7 million on February 3, 2023. The aggregate revised purchase price consists of (a) CAD 3.85 million payable in cash and (b) 7,402,186 common shares in the capital of Avant; plus (i) the amount of the Closing DIP Loan (to the extent not otherwise repaid), to an aggregate of CAD 2.5 million; and (ii) the value of the Assumed Liabilities, subject to certain adjustments (collectively, the “Purchase Price”). On January 31, 2023, the DIP Term Sheet was amended and the principal amount of the DIP Loan was increased by CAD 0.5 million to an aggregate of CAD 2.5 million.
Board Change • Sep 24High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. No experienced directors. No highly experienced directors. Director Tom Flow is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Board Change • Jun 02High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. 2 experienced directors. No highly experienced directors. Independent Director Maurice Levesque is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Board Change • Apr 27High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. 2 experienced directors. No highly experienced directors. Independent Director Maurice Levesque is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Reported Earnings • Dec 01Third quarter 2021 earnings: EPS in line with expectations, revenues disappointThird quarter 2021 results: CA$0.02 loss per share (up from CA$0.073 loss in 3Q 2020). Net loss: CA$8.77m (loss narrowed 9.7% from 3Q 2020). Revenue missed analyst estimates by 15%. Over the next year, revenue is forecast to grow 149%, compared to a 6.9% growth forecast for the industry in Germany.
Reported Earnings • Sep 01Second quarter 2021 earnings released: CA$0.02 loss per share (vs CA$0.04 loss in 2Q 2020)Second quarter 2021 results: Net loss: CA$7.20m (loss widened 47% from 2Q 2020).
Is New 90 Day High Low • Feb 11New 90-day high: €0.37The company is up 31% from its price of €0.28 on 13 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.78 per share.
Is New 90 Day High Low • Jan 04New 90-day low: €0.20The company is down 23% from its price of €0.27 on 06 October 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €3.07 per share.
Is New 90 Day High Low • Dec 11New 90-day low: €0.23The company is down 18% from its price of €0.27 on 11 September 2020. The German market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €5.06 per share.
Analyst Estimate Surprise Post Earnings • Nov 26Revenue misses expectationsRevenue missed analyst estimates by 0.1%. Over the next year, revenue is forecast to grow 600%, compared to a 2.5% growth forecast for the Pharmaceuticals industry in Germany.
Reported Earnings • Nov 26Third quarter 2020 earnings released: CA$0.07 loss per shareThird quarter 2020 results: Net loss: CA$9.72m (loss narrowed 36% from 3Q 2019).
Is New 90 Day High Low • Oct 01New 90-day low: €0.25The company is down 31% from its price of €0.36 on 03 July 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €5.50 per share.